Related Experiment Video
Updated: Aug 14, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Tirofiban for the treatment of ischaemic stroke
Simone C Bukow1, Michael Daffertshofer, Michael G Hennerici
1Department of Neurology, Universitätsklinikum Mannheim, University of Heidelberg, Germany.
Insights
Tirofiban, a glycoprotein IIb/IIIa antagonist, shows promise for acute ischemic stroke treatment. While experimental data is limited, observational studies suggest potential benefits, warranting further investigation.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Tirofiban is an FDA-approved glycoprotein IIb/IIIa receptor antagonist.
- Its current indications include myocardial infarction, unstable angina, and percutaneous coronary intervention for moderate-to-high-risk patients.
- The efficacy of similar agents in myocardial infarction suggests potential utility in acute ischemic stroke.
Purpose of the Study:
- To explore the potential of tirofiban in treating acute ischemic stroke.
- To review existing evidence and identify research gaps regarding tirofiban for stroke.
Main Methods:
- Review of existing literature on glycoprotein IIb/IIIa antagonists, focusing on tirofiban.
- Analysis of observational studies and available trial data (one Phase II trial).
Main Results:
- Observational studies indicate promising outcomes for tirofiban in acute ischemic stroke.
- Limited experimental data exists, but the mechanism of action suggests potential benefit.
- Research has predominantly focused on abciximab, with less emphasis on tirofiban.
Conclusions:
- Tirofiban presents a potential therapeutic option for acute ischemic stroke.
- Further experimental and clinical trials are needed to establish its efficacy and safety in stroke patients.
- The findings highlight the need for increased research into tirofiban for neurological applications.
Abstract:
Tirofiban is one of three glycoprotein IIb/IIIa receptor antagonists approved by the US FDA, beside abciximab and eptifibatide. The approval of tirofiban covers conservative treatment of myocardial infarction and unstable angina, as well as percutaneous coronary intervention, for which treatment with tirofiban is recommended in moderate-to-high-risk patients. The efficacy of glycoprotein IIb/IIIa antagonists in myocardial infarction indicated that these agents may also be helpful in the treatment of acute ischaemic stroke. Although experimental data are lacking, observational studies are promising. In recent years, increasing effort in studying glycoprotein IIb/IIIa antagonists has been made, mostly for treatment with abciximab. However, there is one Phase II trial that investigated treatment with tirofiban.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

